Published in Mycopathologia on July 11, 2017
Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev (2007) 15.66
Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis (2015) 4.07
Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria. Drug Resist Updat (2011) 3.40
Do in vitro susceptibility data predict the microbiologic response to amphotericin B? Results of a prospective study of patients with Candida fungemia. J Infect Dis (1998) 2.61
Epidemiology and outcomes of candidemia in 3648 patients: data from the Prospective Antifungal Therapy (PATH Alliance®) registry, 2004-2008. Diagn Microbiol Infect Dis (2012) 1.88
Molecular mechanisms of fluconazole resistance in Candida dubliniensis isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis. Antimicrob Agents Chemother (2002) 1.46
Worrisome trends in incidence and mortality of candidemia in intensive care units (Paris area, 2002-2010). Intensive Care Med (2014) 1.45
Triazole and echinocandin MIC distributions with epidemiological cutoff values for differentiation of wild-type strains from non-wild-type strains of six uncommon species of Candida. J Clin Microbiol (2011) 1.29
Prevalence of Candida dubliniensis fungemia at a large teaching hospital. Clin Infect Dis (2005) 1.23
Factors influencing caspofungin plasma concentrations in patients of a surgical intensive care unit. J Antimicrob Chemother (2007) 1.20
Use of a serum-based antifungal susceptibility assay to predict the in vivo efficacy of novel echinocandin compounds. Microbiol Immunol (2008) 1.11
Echinocandin resistance, susceptibility testing and prophylaxis: implications for patient management. Drugs (2014) 1.10
Prognostic factors and historical trends in the epidemiology of candidemia in critically ill patients: an analysis of five multicenter studies sequentially conducted over a 9-year period. Intensive Care Med (2014) 1.08
Improved detection of Candida sp. fks hot spot mutants by using the method of the CLSI M27-A3 document with the addition of bovine serum albumin. Antimicrob Agents Chemother (2011) 1.04
Candida dubliniensis: an appraisal of its clinical significance as a bloodstream pathogen. PLoS One (2012) 1.02
Molecular Characterization of Highly Susceptible Candida africana from Vulvovaginal Candidiasis. Mycopathologia (2015) 0.97
Abdominal candidiasis is a hidden reservoir of echinocandin resistance. Antimicrob Agents Chemother (2014) 0.95
Epidemiology, antifungal susceptibility, and pathogenicity of Candida africana isolates from the United Kingdom. J Clin Microbiol (2013) 0.92
Candida dubliniensis meningitis as delayed sequela of treated C. dubliniensis fungemia. Emerg Infect Dis (2008) 0.91
Candida africana and its closest relatives. Mycoses (2010) 0.91
The ever-evolving landscape of candidaemia in patients with acute leukaemia: non-susceptibility to caspofungin and multidrug resistance are associated with increased mortality. J Antimicrob Chemother (2015) 0.91
Echinocandins: production and applications. Appl Microbiol Biotechnol (2013) 0.90
Fluconazole susceptibility testing of Candida inconspicua clinical isolates: comparison of four methods. J Antimicrob Chemother (2005) 0.89
Plasma and peritoneal fluid population pharmacokinetics of micafungin in post-surgical patients with severe peritonitis. J Antimicrob Chemother (2015) 0.88
Update on Antifungal Drug Resistance. Curr Clin Microbiol Rep (2015) 0.87
Altered Micafungin Pharmacokinetics in Intensive Care Unit Patients. Antimicrob Agents Chemother (2015) 0.86
Efficacy and safety of micafungin for treating febrile neutropenia in hematological malignancies. Am J Hematol (2010) 0.85
Rapid discrimination between Candida albicans and Candida dubliniensis by using real-time polymerase chain reaction. Diagn Microbiol Infect Dis (2007) 0.84
Antifungal activity of micafungin in serum. Antimicrob Agents Chemother (2009) 0.83
Examination of the in vitro fungicidal activity of echinocandins against Candida lusitaniae by time-killing methods. J Antimicrob Chemother (2012) 0.82
Ascitic Fluid Analysis in the Differential Diagnosis of Ascites: Focus on Cirrhotic Ascites. J Clin Transl Hepatol (2014) 0.82
First reported case of endocarditis caused by Candida dubliniensis. J Clin Microbiol (2005) 0.81
Distribution of micafungin in the tissue fluids of patients with invasive fungal infections. J Infect Chemother (2011) 0.81
Uncommon Candida Species Fungemia among Cancer Patients, Houston, Texas, USA. Emerg Infect Dis (2015) 0.79
Comparison of the in vitro activity of echinocandins against Candida albicans, Candida dubliniensis, and Candida africana by time-kill curves. Diagn Microbiol Infect Dis (2015) 0.77
Slow response of invasive Candida krusei infection to amphotericin B in a clinical time-kill study. Eur J Clin Microbiol Infect Dis (2006) 0.77
Comparison of in vitro and vivo efficacy of caspofungin against Candida parapsilosis, C. orthopsilosis, C. metapsilosis and C. albicans. Mycopathologia (2012) 0.77
Killing rates exerted by caspofungin in 50 % serum and its correlation with in vivo efficacy in a neutropenic murine model against Candida krusei and Candida inconspicua. J Med Microbiol (2013) 0.77
Micafungin therapy in a critically ill, morbidly obese patient. J Antimicrob Chemother (2011) 0.77
Killing Rates of Caspofungin in 50 Percent Serum Correlate with Caspofungin Efficacy Against Candida albicans in a Neutropenic Murine Model. Curr Drug Deliv (2016) 0.77
Candida dubliniensis Pneumonia: A Case Report and Review of Literature. Mycopathologia (2016) 0.76
Decreased Killing Activity of Micafungin Against Candida guilliermondii, Candida lusitaniae, and Candida kefyr in the Presence of Human Serum. Microb Drug Resist (2017) 0.76
Diagnosis and outcome of early pleural space infection following lung transplantation. Chest (2008) 0.76